UNSPSC 51343813: Efavirenz and lamivudine/zidovudine

This classification denotes a combination drug for treatment of HIV. This is for copackaged product. The first component, EFAVIRENZ, has US FDA Unique Ingredient Identifier of JE6H2O27P8. The second component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The third component, ZIDOVUDINE, has US FDA Unique Ingredient Identifier of 4B9XT59T7S.

UNSPSC 51343813 Efavirenz and lamivudine/zidovudine is a Commodity code covering antiretroviral pharmaceutical products for HIV treatment; state and local procurement activity under this code does not appear in recent state and local contract opportunities. The most recent opportunities tagged to this code span pharmaceutical procurement broadly—including pharmacy services for long-term care facilities, emergency medical supply distribution networks, forensic drug standards, and naloxone procurement—but do not reflect solicitation or contracting activity specific to HIV antiretroviral medications.

The opportunities that did appear under this code involve distinct pharmaceutical and public health products and procurement models: Dane County's RFP for comprehensive pharmacy services to Badger Prairie Health Care Center (proposals due October 22, 2026) covers distributed medication management, dispensing, and billing across multiple payor sources for a long-term care population, with a five-year contract term and an existing annual funding level of $125,000; the City of Tucson Fire Department's RFP for BLS and ALS pharmaceuticals, supplies, and vending-machine software (proposals due June 24, 2026) encompasses centralized procurement and point-of-use distribution through smart lockers and vending systems under a one-year initial term with four one-year renewal options; West Texas Centers for Mental Health and Mental Retardation's RFP for prescription and pharmacy services (proposals due August 21, 2026) covers medication purchasing, inventory management, and dispensing across psychiatric and therapeutic categories for over 7,000 individuals in 23 counties; and Seminole County's IFB for naloxone and drug deactivation systems (originally due July 26, 2023) sought 1,900 units of naloxone annually through a two-year contract with one-year renewal option. The code shows minimal activity specific to antiretroviral HIV medications in current state and local procurement channels.